SXR, a novel steroid and xenobiotic-sensing nuclear receptor.

An important requirement for physiologic homeostasis is the detoxification and removal of endogenous hormones and xenobiotic compounds with biological activity. Much of the detoxification is performed by cytochrome P-450 enzymes, many of which have broad substrate specificity and are inducible by hundreds of different compounds, including steroids. The ingestion of dietary steroids and lipids induces the same enzymes; therefore, they would appear to be integrated into a coordinated metabolic pathway. Instead of possessing hundreds of receptors, one for each inducing compound, we propose the existence of a few broad specificity, low-affinity sensing receptors that would monitor aggregate levels of inducers to trigger production of metabolizing enzymes. In support of this model, we have isolated a novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), which activates transcription in response to a diversity of natural and synthetic compounds. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P-450 genes and is expressed in tissues in which these catabolic enzymes are expressed. These results strongly support the steroid sensor hypothesis and suggest that broad specificity sensing receptors may represent a novel branch of the nuclear receptor superfamily.

[1]  I. Abdu-Aguye,et al.  The effect of single does of rifampicin on the pharmacokinetics of oral nifedipine. , 1997, Journal of pharmaceutical and biomedical analysis.

[2]  J. Kolars,et al.  First-pass metabolism of cyclosporin by the gut , 1991, The Lancet.

[3]  R. Evans,et al.  Ligation independent cloning irrespective of restriction site compatibility. , 1997, Nucleic acids research.

[4]  R. Evans,et al.  Characterization of an autoregulated response element in the mouse retinoic acid receptor type beta gene. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Evans,et al.  Primary structure and expression of a functional human glucocorticoid receptor cDNA , 1985, Nature.

[6]  K. Umesono,et al.  Unique response pathways are established by allosteric interactions among nuclear hormone receptors , 1995, Cell.

[7]  S. Matern,et al.  Stimulation of bile acid 6 alpha-hydroxylation by rifampin. , 1996, Journal of hepatology.

[8]  Peter J. Brown,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors α and γ , 1997 .

[9]  J. Gustafsson,et al.  Fatty acids activate a chimera of the clofibric acid-activated receptor and the glucocorticoid receptor. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Barry M. Forman,et al.  Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ , 1997 .

[11]  F. Gonzalez,et al.  Human cytochromes P450: problems and prospects. , 1992, Trends in pharmacological sciences.

[12]  K. Umesono,et al.  LXR, a nuclear receptor that defines a distinct retinoid response pathway. , 1995, Genes & development.

[13]  D. Moore,et al.  A new orphan member of the nuclear hormone receptor superfamily that interacts with a subset of retinoic acid response elements , 1994, Molecular and cellular biology.

[14]  Jameyla A. Ladias,et al.  Regulation of the apolipoprotein AI gene by ARP-1, a novel member of the steroid receptor superfamily , 1991, Science.

[15]  K. Stringer,et al.  Enhanced Pirmenol Elimination by Rifampin , 1988, Journal of clinical pharmacology.

[16]  G. Reimondo,et al.  Misdiagnosis of Cushing's syndrome in a patient receiving rifampicin therapy for tuberculosis. , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[17]  K. Umesono,et al.  Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors , 1991, Cell.

[18]  P. Watkins,et al.  Complete cDNA sequence of a cytochrome P-450 inducible by glucocorticoids in human liver. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[19]  V. Kyriazopoulou,et al.  Rifampicin-induced adrenal crisis in addisonian patients receiving corticosteroid replacement therapy. , 1984, The Journal of clinical endocrinology and metabolism.

[20]  J. Lehmann,et al.  An Orphan Nuclear Receptor Activated by Pregnanes Defines a Novel Steroid Signaling Pathway , 1998, Cell.

[21]  Joseph L. Napoli,et al.  Vitamin D Metabolism , 1984 .

[22]  E. C. Dodds Hormones. , 1946, Health education journal.

[23]  F. Guengerich Metabolism of 17 α-ethynylestradiol in humans , 1990 .

[24]  Rodger Staden,et al.  The current status and portability of our sequence handling software , 1986, Nucleic Acids Res..

[25]  T. H. Zawawi,et al.  The effects of therapy with rifampicin and isoniazid on basic investigations for Cushing’s syndrome , 1996, Irish journal of medical science.

[26]  E. Myers,et al.  Basic local alignment search tool. , 1990, Journal of molecular biology.

[27]  S. Matern,et al.  Stimulation of bile acid 6α-hydroxylation by rifampin , 1996 .

[28]  K. Umesono,et al.  BXR, an embryonic orphan nuclear receptor activated by a novel class of endogenous benzoate metabolites. , 1998, Genes & development.

[29]  Miguel Beato,et al.  Steroid hormone receptors: Many Actors in search of a plot , 1995, Cell.

[30]  P. Beaune,et al.  Isolation and sequence determination of a cDNA clone related to human cytochrome P-450 nifedipine oxidase. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[31]  O. M. Edwards,et al.  Changes in cortisol metabolism following rifampicin therapy. , 1974, Lancet.

[32]  J. Kolars,et al.  Identification of rifampin-inducible P450IIIA4 (CYP3A4) in human small bowel enterocytes. , 1992, The Journal of clinical investigation.

[33]  H. Selye Hormones and resistance. , 1970, Journal of pharmaceutical sciences.

[34]  G. Wilkinson,et al.  Induction of propranolol metabolism by rifampicin. , 1983, British journal of clinical pharmacology.

[35]  J. Devereux,et al.  A comprehensive set of sequence analysis programs for the VAX , 1984, Nucleic Acids Res..

[36]  P. Lønning,et al.  Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin. , 1989, Journal of steroid biochemistry.

[37]  E. Schuetz,et al.  Paradoxical transcriptional activation of rat liver cytochrome P-450 3A1 by dexamethasone and the antiglucocorticoid pregnenolone 16 alpha-carbonitrile: analysis by transient transfection into primary monolayer cultures of adult rat hepatocytes. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[38]  R. Tukey,et al.  Trans-species gene transfer for analysis of glucocorticoid-inducible transcriptional activation of transiently expressed human CYP3A4 and rabbit CYP3A6 in primary cultures of adult rat and rabbit hepatocytes. , 1996, Molecular pharmacology.

[39]  K. Umesono,et al.  Determinants for selective RAR and TR recognition of direct repeat HREs. , 1993, Genes & development.

[40]  F. Guengerich Metabolism of 17 alpha-ethynylestradiol in humans. , 1990, Life sciences.

[41]  R. Evans,et al.  A retinoic acid-triggered cascade of HOXB1 gene activation. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[42]  G. Kondos,et al.  Near-total reduction in verapamil bioavailability by rifampin. Electrocardiographic correlates. , 1988, Chest.

[43]  William Bourguet,et al.  A canonical structure for the ligand-binding domain of nuclear receptors , 1996, Nature Structural Biology.

[44]  J. Idle,et al.  The role of individual human cytochromes P450 in drug metabolism and clinical response. , 1992, Trends in pharmacological sciences.

[45]  E. Schuetz,et al.  Induction of cytochrome P-450 by glucocorticoids in rat liver. II. Evidence that glucocorticoids regulate induction of cytochrome P-450 by a nonclassical receptor mechanism. , 1984, The Journal of biological chemistry.

[46]  Slobodan Petar Rendic,et al.  Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. , 1997, Drug metabolism reviews.

[47]  O. Hankinson The aryl hydrocarbon receptor complex. , 1995, Annual review of pharmacology and toxicology.

[48]  P. Thompson,et al.  Rifampicin reduces effectiveness and bioavailability of prednisolone. , 1983, British medical journal.

[49]  M. Baker Endocrine Activity of Plant-Derived Compounds: An Evolutionary Perspective , 1995, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[50]  P. Fernández-Salguero,et al.  The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. , 1995, Pharmacogenetics.

[51]  M. Denison,et al.  Xenobiotic-inducible Transcription of Cytochrome P450 Genes (*) , 1995, The Journal of Biological Chemistry.

[52]  R. Evans,et al.  Colocalization of DNA-binding and transcriptional activation functions in the human glucocorticoid receptor , 1987, Cell.

[53]  D. Nebert,et al.  Pregnenolone 16 alpha-carbonitrile-inducible P-450 gene family: gene conversion and differential regulation , 1986, Molecular and cellular biology.

[54]  M. Fromm,et al.  The nifedipine-rifampin interaction. Evidence for induction of gut wall metabolism. , 1996, Drug metabolism and disposition: the biological fate of chemicals.

[55]  J. D. Wilson,et al.  Steroid 5 alpha-reductase: two genes/two enzymes. , 1994, Annual review of biochemistry.

[56]  J. Lehmann,et al.  Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[57]  R. Evans,et al.  The RXR heterodimers and orphan receptors , 1995, Cell.

[58]  V. Kyriazopoulou,et al.  Abnormal overnight dexamethasone suppression test in subjects receiving rifampicin therapy. , 1992, The Journal of clinical endocrinology and metabolism.

[59]  K. Umesono,et al.  The nuclear receptor superfamily: The second decade , 1995, Cell.